New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
11:52 EDTPCLN, NCR, AGNC, CLDXOptions with increasing implied volatility: NCR CLDX AGNC PCLN
News For NCR;CLDX;AGNC;PCLN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
11:12 EDTPCLNPriceline rises after Stifel says European macro risks already priced in
The shares of online travel agency Priceline (PCLN) are advancing in a down market after Stifel upgraded the stock, saying that the European macro economic risks faced by the company are priced into the shares at current levels, while the stock's valuation is compelling. WHAT'S NEW: The macro economic risks that Priceline faces in Europe are already priced into the stock, Stifel analyst Scott Devitt wrote in a note to investors earlier today. Following the stock's recent underperformance spurred by this risk and worries about the stock's valuation, the shares' risk/reward ratio has become attractive, Devitt believes. If the economic situation in Europe improves, Priceline's stock could rise, Devitt said. Citing Priceline's estimated 5% 2015 free cash flow yield, its newly initiated $3B share repurchase program, and its consistent profitable organic growth, the analyst wrote that the company has strong fundamentals and favorable shareholder policies. Moreover, the combination of Priceline's leverage to improvement in Europe, its leading position in its industry, and its compelling valuation make the company unique among mature, growing large-cap Internet companies, according to the analyst, who set a $1,400 price target on the shares. OTHERS TO WATCH: Other companies in Priceline's sector include Expedia (EXPE) and Orbitz (OWW). PRICE ACTION: In mid-morning trading, Priceline rose 2% to $1,172.
10:01 EDTPCLNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:06 EDTPCLNPriceline upgraded to Buy from Hold at Stifel
As previously reported, Stifel upgraded Priceline to Buy from Hold. The firm views risk/reward as attractive given recent underperformance related to European macro risk and free-cash-flow valuation. Stifel believes reset expectations provide provide potential upside from positive surprises and established a $1,400 price target.
06:24 EDTPCLNPriceline upgraded to Buy from Hold at Stifel
Subscribe for More Information
March 26, 2015
08:09 EDTNCRNCR Corp says selected by Qatar National Bank
QNB has signed a software professional services agreement with NCR Corporation to migrate to NCR Consumer Experience Banking, CxBanking, software -- APTRA Activate.
March 25, 2015
08:12 EDTNCRNCR says selected by Defense Commissary Agency
Subscribe for More Information
March 20, 2015
07:00 EDTPCLNPriceline bookings tracking towards upper end of guidance, says Cantor
After conducting checks on global search traffic to Booking.com and other Priceline brands through mid- March, Cantor thinks the checks suggest that the company's bookings are tracking towards the upper end of management's guidance this quarter. The firm keeps a $1,360 price target and Buy rating on the shares.
March 18, 2015
06:02 EDTPCLNPriceline shares inexpensive 'by many measures,' says Piper Jaffray
Piper Jaffray says its conclusion from several valuation analyses is that shares of Priceline are inexpensive "by many measures." When compared to a comp group of hotel companies, the stock trades at a "material discount," Piper states. It believes shares are worth in excess of its $1,375 price target. The firm reiterates an Overweight rating on the name.
March 17, 2015
09:25 EDTCLDXOn The Fly: Pre-market Movers
Subscribe for More Information
08:13 EDTCLDXCelldex announces clinical trial collaboration with Roche
Celldex Therapeutics (CLDX) announced that it has entered into a clinical trial collaboration with Roche (RHHBY) to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex's CD27 targeting investigational antibody, and MPDL3280A, Roche's investigational cancer immunotherapy in a Phase 1/2 study in renal cell carcinoma. Varlilumab and MPDL3280A are part of a new class of investigational medicines known as cancer immunotherapies that are designed to harness the body's own immune system to fight cancer through separate yet complementary mechanisms of action that may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells. Preclinical data suggest the combination of these two mechanisms are synergistic and may enhance anti-tumor immune response compared to either agent alone. In Celldex's Phase 1 study of varlilumab in multiple solid tumors, promising signs of clinical activity in patients with refractory renal cell carcinoma were observed, including a durable partial response that has continued to decrease in tumor volume over time and prolonged stable disease. Under the terms of this agreement, Roche will provide study drug and Celldex will be responsible for conducting and funding the study, which is expected to begin in 2015.
08:07 EDTNCRWaffle House completes rollout of NCR Silver to 1,400 corporate locations
Subscribe for More Information
08:05 EDTNCRNCR Interactive Teller selected by Akbank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use